Connect with us

Health

Cara Therapeutics Inc (NASDAQ:CARA) Recent Business Highlights

Published

on

In October 2017, Cara Therapeutics Inc (NASDAQ:CARA) reported the successful conclusion of its End-of-Phase II discussions with the U.S. FDA. The firm, in consultation with the FDA, has set the major elements of the Phase III registrational plan for the cure of moderate-to-severe CKD-aP in people undergoing hemodialysis. The firm anticipates to commence the first pivotal study of I.V. CR845 in hemodialysis subjects with CKD-aP in 4Q17.

The details

In October 2017, Cara Therapeutics reported dosing of the first patient in a Phase I safety and pharmacokinetic study of Oral CR845 tablets in subjects with Stage 3-V CKD who are not on dialysis. Report from the study is anticipated to inform design and dose selection of the planned Phase II study in non-hemodialysis subjects with CKD-aP.

The underway adaptive Phase III study of I.V. CR845 for the cure of acute postoperative pain progresses with patients’ enrollment undergoing abdominal surgery, with registration completion anticipated by year-end 2017 or early 2018.

In the month of August, Cara Therapeutics reported the engagement of Mani Mohindru, Ph.D., as Chief Strategy Officer and Chief Financial Officer. Josef Schoell, who had served as the CFO at Cara for over a decade, retired from the firm. The firm anticipates to make presentations at the upcoming conferences through November 2017, including Stifel Healthcare Conference on November 14 in New York; Jefferies London Healthcare Conference on November 16 in London, UK; and 29th Annual Piper Jaffray Healthcare Event on November 28 in New York, NY.

Depending on timing expectations and estimated costs for ongoing clinical development plans, Cara Therapeutics reported that its anticipates that its available-for-sale marketable securities and existing cash/cash equivalents will be sufficient for the firm to fund its capital expenditure as well as operating expenses requirements into 2019, without providing effect to any prospective milestone payments under current collaborations.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of journaltranscript.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure

BRANDS

DETAILS

SCORE

PRODUCT SITES

  • Certified Organic
  • Made In U.S.A
  • Purity Promise
  • Price From $49

9.8

30% OFF Today! “30 0FF”

  • All Natural
  • Made In U.S.A
  • Lab Tested
  • Price From $69

9.7

  • All Natural
  • Made In U.S.A
  • Dissolvable Oral
  • Price From $99

9.6

  • All Natural
  • Made In U.S.A
  • Oral Mist
  • Price From $39

9.5

BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Purity Promise
  • Price From $49
SCORE

9.8

PRODUCT SITE
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Lab Tested
  • Price From $69
SCORE

9.7

PRODUCT SITE VIEW PRODUCTS
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Dissolvable Oral
  • Price From $99
SCORE

9.6

PRODUCT SITE VIEW PRODUCTS
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Oral Mist
  • Price From $39
SCORE

9.5

PRODUCT SITE VIEW PRODUCTS
Advertisement
Advertisement

Symbol        Alert        High        Gain

 

  VBIO          $0.67       $4.10      500%

  IMLFF        $0.11       $0.57      400%

  CMXC        $0.25       $0.45      80%

  REPCF       $0.54       $0.79      48%

 

Get Your Latest Winner Delivered to Your Inbox!

FREE

For The Next 48 Hours

Advertisement
Advertisement
Advertisement
Advertisement
Advertisement